Michael L. Jackson, PhD, MPH
Research interests and experience
- Epidemiology of infectious diseases: Disease burden, risk factors, transmission dynamics, surveillance and response
- Vaccine effectiveness: Methodology, removing bias in effectiveness estimates
- Vaccine safety: Rates of adverse events, safety of new vaccines
Michael L. Jackson’s research focuses on understanding how infectious diseases spread, and on designing and evaluating interventions such as vaccination programs. Dr. Jackson is the Group Health Research Institute (GHRI) principal investigator for the United States Influenza Vaccine Effectiveness Network. This Network aims to provide ongoing evaluations of the U.S. influenza vaccination program. Dr. Jackson uses data from this Network to study influenza vaccine effectiveness, to estimate the burden of disease caused by influenza, and to advance the methodology of vaccine effectiveness studies. He also uses mathematical models to predict the impact of vaccination programs on the spread of infectious diseases such as Haemophilus influenza type b (Hib) and Neisseria meningitidis.
Dr. Jackson is a co-investigator on the Vaccine Safety Datalink (VSD) Project. The VSD, a collaboration between nine U.S. managed care organizations and the Centers for Disease Control and Prevention (CDC), is the world’s premier system for post-licensure studies of vaccine safety. As a VSD co-investigator, Dr. Jackson leads studies of the safety of childhood immunizations and develops methods for using managed care data for vaccine safety studies.
While studying for his PhD at the University of Washington, Dr. Jackson was a graduate research associate with GHRI from 2002 to 2007, and then a postdoctoral fellow at GHRI from 2007 to 2008. He then spent two years as an Epidemic Intelligence Service (EIS) officer with the CDC in Atlanta. As an EIS officer, Dr. Jackson helped lead investigations of whooping cough outbreaks and of the 2009 influenza pandemic. He also designed and oversaw an enhanced surveillance system for invasive Hib disease in the U.S. during the 2008-2009 shortage of Hib vaccines. He returned to GHRI as an assistant investigator in 2010.
Osterholm MT, Kelley NS, Belongia EA, Jackson LA, Jackson ML. Reply: Cochrane rearranged. Vaccine. 2014 Feb 13. pii: S0264-410X(14)00160-1. doi [Epub ahead of print]. PubMed
Ohmit SE, Thompson MG, Petrie JG, Thaker SN, Jackson ML, Belongia EA, Zimmerman RK, Gaglani M, Lamerato L, Spencer SM, Jackson L, Meece JK, Nowalk MP, Song J, Zervos M, Cheng PY, Rinaldo CR, Clipper L, Shay DK, Piedra P, Monto AS. Influenza vaccine effectiveness in the 2011-2012 season: protection against each circulating virus and the effect of prior vaccination on estimates. Clin Infect Dis. 2013 Nov 13 [Epub ahead of print]. PubMed
Jackson ML, Yu O, Nelson JC, Naleway A, Belongia EA, Baxter R, Narwaney K, Jacobsen SJ, Shay DK, Jackson LA. Further evidence for bias in observational studies of influenza vaccine effectiveness: the 2009 Influenza A(H1N1) pandemic. Am J Epidemiol. 2013 Oct 15;178(8):1327-36. doi: 10.1093/aje/kwt124. Epub 2013 Aug 26. PubMed
Dublin S, Baldwin E, Walker RL, Christensen LM, Haug PJ, Jackson ML, Nelson JC, Ferraro J, Carrell D, Chapman WW. Natural language processing to identify pneumonia from radiology reports. Pharmacoepidemiol Drug Saf. 2013 Aug;22(8):834-41. doi: 10.1002/pds.3418. Epub 2013 Apr 1. PubMed
Nelson JC, Marsh T, Lumley T, Larson EB, Jackson LA, Jackson ML; Vaccine Safety Datalink Team. Validation sampling can reduce bias in health care database studies: an illustration using influenza vaccination effectiveness. J Clin Epidemiol. 2013 Aug;66(8 Suppl):S110-21. doi: 10.1016/j.jclinepi.2013.01.015. PubMed
McCarthy NL, Weintraub E, Vellozzi C, Duffy J, Gee J, Donahue JG, Jackson ML, Lee GM, Glanz J, Baxter R, Lugg MM, Naleway A, Omer SB, Nakasato C, Vazquez-Benitez G, DeStefano F. Mortality rates and cause-of-death patterns in a vaccinated population. Am J Prev Med. 2013;45(1):91-7. doi: 10.1016/j.amepre.2013.02.020. PubMed
Greene SK, Rett MD, Vellozzi C, Kulldorff M, Marcy SM, Daley MF, Belongia EA, Baxter R, Fireman BH, Jackson ML, Omer SB, Nordin JD, Jin R, Weintraub ES, Vijayadeva V, Lee GM. Guillain-Barré Syndrome, influenza vaccination, and antecedent respiratory and gastrointestinal infections: a case-centered analysis in the Vaccine Safety Datalink, 2009-2011. PLoS One. 2013 Jun 26;8(6):e67185. Print 2013. PubMed
Tartof S, Cohn A, Tarbangdo F, Djingarey MH, Messonnier N, Clark TA, Kambou JL, Novak R, Diomande FV, Medah I, Jackson ML. Identifying optimal vaccination strategies for serogroup A Neisseria meningitidis conjugate vaccine in the African meningitis belt. PLoS One. 2013 May 9;8(5):e63605. doi: 10.1371/journal.pone.0063605. Print 2013. PubMed
Jackson ML, Nelson JC. The test-negative design for estimating influenza vaccine effectiveness. Vaccine. 2013 Apr 19;31(17):2165-8. doi: 10.1016/j.vaccine.2013.02.053. Epub 2013 Mar 13. PubMed
Jackson ML. Challenges in comparing the safety of different vaccination schedules. Vaccine. 2013 Apr 19;31(17):2126-9. doi: 10.1016/j.vaccine.2013.02.054. Epub 2013 Mar 5. PubMed
To view more publications, please see Dr. Jackson’s CV.